Drug Trial Radar · NCT04537208
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
441
Actual
Start
Sep 3, 2020
Primary completion
Nov 19, 2021
Study completion Nov 19, 2021
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Sep 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objectives of the study were: * To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group. * To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last injection. The secondary objectives of the study are: * To describe binding antibody profile at Day 1, Day 22, Day 36, Day 181 (Cohort 1) or Day 202 (Cohort 2), and Day 366 (Cohort 1) or Day 387 (Cohort 2) of each study intervention group. * To describe the neutralizing antibody profile at Day 181 (Cohort 1) or Day 202 (Cohort 2) and at Day 366 (Cohort 1) and Day 387 (Cohort 2) of each study intervention group. * To describe the occurrence of virologically-confirmed coronavirus disease (COVID-19)-like illness and serologically-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. * To evaluate the correlation / association between antibody responses to SARS-CoV-2 Recombinant Protein and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.
Conditions
- COVID-19 (Healthy Volunteers)
Interventions
CoV2 preS dTM-AF03 (low-dose)Biological
Pharmaceutical form: liquid; route of administration: intramuscular injection
CoV2 preS dTM-AF03 (high-dose)Biological
Pharmaceutical form: liquid; route of administration: intramuscular injection
CoV2 preS dTM-AS03 (low-dose)Biological
Pharmaceutical form: liquid; route of administration: intramuscular injection
CoV2 preS dTM-AS03 (high-dose)Biological
Pharmaceutical form: liquid; route of administration: intramuscular injection
CoV2 preS dTM (high-dose) without adjuvantBiological
Pharmaceutical form: liquid; route of administration: intramuscular injection
Placebo (0.9% normal saline)Biological
Pharmaceutical form: liquid; route of administration: intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1Time frame: Day 1 (pre-vaccination)
- Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 22Time frame: Day 22 (post-vaccination)
- Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 36Time frame: Day 36 (post-vaccination)
- Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
- Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)
- Number of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
- Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)
- Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22Time frame: Day 22 (post-vaccination)
- Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36Time frame: Day 36 (post-vaccination)
- Number of Participants With Immediate Unsolicited Adverse Events (AEs)Time frame: Within 30 minutes post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
- Number of Participants With Solicited Injection Site ReactionsTime frame: Within 7 days post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
- Number of Participants With Solicited Systemic ReactionsTime frame: Within 7 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])
- Number of Participants With Unsolicited Adverse EventsTime frame: Within 21 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])
- Number of Participants With Medically Attended Adverse Events (MAAE)Time frame: From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)
- Number of Participants With Serious Adverse Events (SAE)Time frame: From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)
- Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)
- Number of Participants With Laboratory Test Results Based on US FDA Toxicity Grading GuidanceTime frame: From Day 1 up to 8 days post last dose (i.e., up to Day 9 for Cohort 1 and up to Day 30 for Cohort 2)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 8400004
Birmingham, Alabama
Investigational Site Number 8400012
Rolling Hills Estates, California
Investigational Site Number 8400011
Hollywood, Florida
Investigational Site Number 8400019
Melbourne, Florida
Investigational Site Number 8400016
Boston, Massachusetts
Investigational Site Number 8400002
Omaha, Nebraska
Investigational Site Number 8400001
Rochester, New York
Investigational Site Number 8400007
Rochester, New York
Investigational Site Number 8400008
Cleveland, Ohio
Investigational Site Number 8400003
Philadelphia, Pennsylvania
Investigational Site Number 8400014
Mt. Pleasant, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.